TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Stanford University
M.D. Anderson Cancer Center
Massachusetts General Hospital
Novartis
Clinical Hub for Interventional Research (CHOIR)
Indiana University
Crossbow Therapeutics, Inc.
Fred Hutchinson Cancer Center
City of Hope Medical Center
Roswell Park Cancer Institute
Mayo Clinic
Solu Therapeutics, Inc
NextCure, Inc.
Prelude Therapeutics
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Kahr Medical
Massachusetts General Hospital
Mayo Clinic
Janssen Research & Development, LLC
University of Alabama at Birmingham
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Massachusetts General Hospital
Amgen
Foghorn Therapeutics Inc.
Eli Lilly and Company
University of Virginia
Merck Sharp & Dohme LLC
Novartis
Tr1X, Inc.
National Cancer Institute (NCI)
AbbVie
M.D. Anderson Cancer Center
Epigenetix, Inc.
Takeda
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
Fox Chase Cancer Center
City of Hope Medical Center
OHSU Knight Cancer Institute
Hemavant Sciences GmbH
Guangzhou Lupeng Pharmaceutical Company LTD.
Prelude Therapeutics
Pfizer
Nanexa AB
M.D. Anderson Cancer Center